Sterling Pharma Solutions acquired by GHO Capital

A majority equity stake in British active pharmaceutical ingredients (API) contract development and manufacturing organization Sterling Pharma Solutions has been acquired by GHO Capital following its impressive growth. The acquisition, the value of which was not disclosed, will pave the way for further growth in 2019 and the coming years.

Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of complex and difficult to manufacture API development and manufacturing, with a reputation for world class quality standards. This is reflected in Sterling’s long-term relationships with blue-chip pharmaceutical and animal health clients, as well as a strong track record with global regulators including the Food and Drug Administration and European Medicine Agency.

Outsourced small molecule API development and manufacturing is growing steadily at around 7% per annum. This is overlaid with a long-term trend towards increasing molecule complexity, driving higher market growth rates in complex chemistry, where Sterling is an industry leader in Europe.